GO
Loading...

Regeneron Pharmaceuticals Inc

More

  • WASHINGTON, Jan 30- The United States has proposed analyzing genetic information from more than 1 million American volunteers as part of a new initiative to understand human disease and develop medicines targeted to an individual's genetic make-up. Of that, $130 million would go to the NIH to fund the research cohort and $70 million to NIH's National Cancer...

  • Benefits firms shouldn't play drug favorites: CEO Tuesday, 20 Jan 2015 | 10:00 AM ET

    Regeneron Pharmaceuticals CEO Dr. Leonard Schleifer told CNBC on Tuesday that benefits companies should not try to practice medicine.

  • SAN FRANCISCO, Jan 15- The world's biggest drugmakers face a new reality when it comes to U.S. pricing for their products as insurers use aggressive tactics to extract steep price discounts, even for the newest medications. Big Pharma executives acknowledged the depth of change this week during public presentations and interviews with Reuters at the J.P....

  • Midday movers: Wynn Resorts, Chevron, Crocs & more Friday, 9 Jan 2015 | 1:15 PM ET

    Some of Friday's midday movers:

  • These 14 'freight train' stocks can't be stopped Friday, 9 Jan 2015 | 11:07 AM ET

    These stocks are like freight trains on a roll—they keep plowing ahead of the market for going on the sixth straight year, USAT reports.

  • Jan 9- An experimental drug from Sanofi SA and Regeneron Pharmaceuticals was found to be effective in lowering "bad" cholesterol even when administered once every four weeks, instead of every two weeks. Sanofi SA and Regeneron are in a fierce race with Pfizer and Amgen Inc to bring their PCSK9 inhibitor to the market, which is expected to be worth billions if these...

  • Early movers: GPS, SBUX, SHOO, BHI & more Friday, 9 Jan 2015 | 7:56 AM ET
    Traders on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Cramer's 10 lessons learned from 2014 Monday, 5 Jan 2015 | 6:10 PM ET
    Traders on the floor of the New York Stock Exchange.

    On a down day in the market, Jim Cramer thinks this is the perfect time to review the silly preconceptions of 2014.

  • NEW YORK, Dec 26- U.S. stocks rose on Friday, with major indexes hitting records and on track for a second straight weekly advance, though trading was light with many traders still out for the Christmas holiday. The advance continued Wall Street's recent upward bias, with the S&P up about 6 percent from a recent closing low hit earlier this month.

  • NEW YORK, Dec 26- U.S. stocks rose on Friday, with major indexes hitting records and on track for a second straight weekly advance, though trading was light with many traders still out for the Christmas holiday. The advance continued Wall Street's recent upward bias, with the S&P up about 6 percent from a recent closing low hit earlier this month.

  • *Dow, S&P rise for 5th day, both end at records. NEW YORK, Dec 23- U.S. stocks rose on Tuesday, with the Dow closing above 18,000 for the first time ever and the S&P 500 ending at a record after an unexpectedly strong report on economic growth. The Dow rose as high as 18,069.22 and is up about 175 percent from a 12- year closing low hit on March 9, 2009.

  • NEW YORK, Dec 23- U.S. stocks rose for a fifth straight session on Tuesday, with the Dow climbing above 18,000 for the first time ever after an unexpectedly strong report on economic growth. Both the Dow and S&P 500 hit intraday records, and the S&P is on track for its 51st record close of 2014. The gains pushed the Dow as high as 18,051.14, and the blue-chip index is now up...

  • Cramer: Watch out Regeneron, here comes Isis Thursday, 18 Dec 2014 | 6:33 PM ET

    Jim Cramer is always looking for the next big biotech stock. He has found one that is a real game-changer, thanks to this new drug.

  • Cramer’s perfect recipe for a Santa Claus rally Thursday, 18 Dec 2014 | 6:13 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Jim Cramer is seeing some good signs in the economy right now. Could they be the perfect ingredients for a Santa Claus rally?

  • Lightning Round: Good stock with a good yield Wednesday, 17 Dec 2014 | 6:57 PM ET

    Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • FRANKFURT, Dec 15- Bayer's eye medication Eylea does not offer an advantage over a rival product from Novartis when treating patients with a type of diabetes-related swelling of the retina, a German healthcare cost watchdog said on Monday. IQWiG compared trial data on Eylea and Novartis's Lucentis for treatment of diabetic macular edema and found there was no...

  • Midday movers: McDonald's, Sony, Celgene & more Monday, 8 Dec 2014 | 1:12 PM ET

    Some of Monday's midday movers:

  • Lightning Round: Time to buy buy buy for 2015 Thursday, 4 Dec 2014 | 6:50 PM ET

    Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Cramer's heated love affair with biotech Tuesday, 2 Dec 2014 | 6:33 PM ET
    File photo: Michael LeClair, left, and Kevin Fleurimond, in the manufacturing room of Biogen Idec.

    As the global economy faces headwinds each day, Jim Cramer knows this group can withstand stormy weather more often than the rest.

  • Cramer Remix: This industry isn't dead yet! Monday, 24 Nov 2014 | 7:08 PM ET

    A big positive sign in this once left-for-dead sector has turned Cramer's attention to a handful of stocks that could go higher.